Abstract
Pancreatic cancer is an aggressive tumor associated with poor survival, and early detection is important to improve patient outcomes. In the present study, we examined MIR1246 expression as a biomarker of pancreatic cancer. Total RNA was extracted from serum, urine and saliva samples from healthy subjects (n = 30) and patients with pancreatic cancer (n = 41, stage 0–IV). The MIR1246 level in each fluid was analyzed by quantitative reverse transcription-polymerase chain reaction. Significantly higher MIR1246 expression in serum and urine was observed in patients with cancer than in healthy controls. A significant positive correlation was found between serum and urine MIR1246 expression (r = 0.34). Receiver operating characteristic curves were constructed for MIR1246 in all three body fluids. The area under the curve for serum MIR1246 was 0.87 (sensitivity, 92.3%; specificity, 73.3%), and that for urine MIR1246 was 0.90 (sensitivity, 90.2%; specificity, 83.3%). With a cut-off of the control group’s mean plus twice the standard deviation, the sensitivities of MIR1246 in serum and urine for pancreatic cancer were 60.9 and 58.5%, respectively. Combining both serum and urine MIR1246 expression yielded a sensitivity of 85%. These results indicate that MIR246 may be a useful diagnostic biomarker for pancreatic cancer.
Highlights
Pancreatic cancer is an aggressive tumor associated with poor survival, and early detection is important to improve patient outcomes
MIR1246 expression in serum and urine was significantly higher in patients with pancreatic cancer than in the healthy controls (p < 0.0001), but the levels in saliva did not differ significantly between the two groups (p = 0.76; Fig. 1)
We compared the expression of MIR1246 in blood, urine and saliva between patients with pancreatic cancer and healthy controls
Summary
Pancreatic cancer is an aggressive tumor associated with poor survival, and early detection is important to improve patient outcomes. With a cut-off of the control group’s mean plus twice the standard deviation, the sensitivities of MIR1246 in serum and urine for pancreatic cancer were 60.9 and 58.5%, respectively. Combining both serum and urine MIR1246 expression yielded a sensitivity of 85% These results indicate that MIR246 may be a useful diagnostic biomarker for pancreatic cancer. In the absence of lymph node or distant metastases from a lesion localized to the pancreas, the 5-year survival is 34.3%, indicating a better prognosis for early-stage disease Such cases of localized pancreatic cancer represent only 10% of all cases[1] because symptoms often do not appear until the disease has progressed[2]. Several reports identified elevated levels of MIR1246 expression in urine and saliva in patients with pancreatic cancer[18,19,20]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
